2026-06-14T03:44:37Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/142392024-09-27T22:49:30Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Hildebrandt, Anke author Zintl, Annetta author Montero-Clemente, Estrella author Hunfeld, Klaus-Peter author Gray, Jeremy author 2021-09-09 Babesiosis is attracting increasing attention as a worldwide emerging zoonosis. The first case of human babesiosis in Europe was described in the late 1950s and since then more than 60 cases have been reported in Europe. While the disease is relatively rare in Europe, it is significant because the majority of cases present as life-threatening fulminant infections, mainly in immunocompromised patients. Although appearing clinically similar to human babesiosis elsewhere, particularly in the USA, most European forms of the disease are distinct entities, especially concerning epidemiology, human susceptibility to infection and clinical management. This paper describes the history of the disease and reviews all published cases that have occurred in Europe with regard to the identity and genetic characteristics of the etiological agents, pathogenesis, aspects of epidemiology including the eco-epidemiology of the vectors, the clinical courses of infection, diagnostic tools and clinical management and treatment. Pathogens. 2021;10(9):1165. 10.3390/pathogens10091165 2076-0817 Pathogens (Basel, Switzerland) 34578196 http://hdl.handle.net/20.500.12105/14239 Babesia divergens Babesia microti Babesia venatorum European babesiosis Ixodes ricinus Clinical cases Diagnosis Epidemiology Parasite identity Treatment Human Babesiosis in Europe